Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has gained attention as a potential treatment option for primary aldosteronism, a condition associated with significant cardiovascular and renal complications. However, robust evidence regarding its efficacy and safety in this patient population remains limited. To address this gap, a clinical evaluation involving 57 patients with primary aldosteronism assessed the therapeutic potential and safety profile of finerenone in managing this endocrine disorder.
The study found that finerenone treatment significantly reduced both ambulatory and office blood pressure in patients with primary aldosteronism after 12 weeks of therapy. Mean daytime ambulatory systolic blood pressure decreased by −6.69±1.60 mm Hg and diastolic blood pressure by −4.55±1.06 mm Hg. Office blood pressure showed even greater reductions, with systolic…
